Razaxaban, a direct factor Xa inhibitor, in combination with aspirin and/ or clopidogrel improves low-dose antithrombotic activity without enhancing bleeding liability in rabbits

Journal of Thrombosis and Thrombolysis

Volumn 24, Issue 1, 2007, Pages 43-51

  Wong, Pancras C ^a   Crain, Earl J ^a   Watson, Carol A ^a   Wexler, Ruth R ^a   Lam, Patrick Y S ^a   Quan, Mimi L ^a   Knabb, Robert M ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Antithrombotic agents; Aspirin; Clopidogrel; Factor Xa inhibitors

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ANTITHROMBOCYTIC AGENT; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; BMS 561389; CLOPIDOGREL; COLLAGEN; GAMMA THROMBIN; PLACEBO; RAZAXABAN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ARTICLE; BLEEDING; BLOOD CLOTTING; CAROTID ARTERY FLOW; CAROTID ARTERY THROMBOSIS; COMBINATION CHEMOTHERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; ELECTROLYSIS; EX VIVO STUDY; HEMATOLOGICAL PARAMETERS; IN VITRO STUDY; LOW DRUG DOSE; MALE; MONOTHERAPY; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PORTAL VEIN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTHROMBIN TIME; RABBIT; THROMBOCYTE AGGREGATION;

ANIMALS; ASPIRIN; BLOOD COAGULATION; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; FACTOR XA; FIBRINOLYTIC AGENTS; HEMORRHAGE; HEMOSTASIS; ISOXAZOLES; MALE; PLATELET AGGREGATION; PYRAZOLES; RABBITS; THROMBOSIS; TICLOPIDINE;

EID: 34249705694     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11239-007-0017-9     Document Type: Article

References (26)

1. Quan ML, Wexler RR (2001) The design and synthesis of noncovalent factor Xa inhibitors. Curr Topics Med Chem 1:137-149
2. Pinto DJ, Orwat MJ, Wang S et al (2001) Discovery of 1-[3-(aminomethyl)phenyl]-N-3-fluoro-2′-(methylsulfonyl) -1H-pyrazole-5-carboxamide (DPC423), a highly potent, selective, and orally bioavailable inhibitor of blood coagulation factor Xa
3. Wong PC, Pinto DJ, Knabb RM (2002) Nonpeptide factor Xa inhibitors: DPC423, a highly potent and orally bioavailable pyrazole antithrombotic agent. Cardiovasc Drug Rev 20:137-152
4. Quan ML, Lam PY, Han Q et al (2005) Discovery of 1-(3′-aminobenzisoxazol-5′-yl)-3-trifluoromethyl-N -[2-fluoro-4-[(2′-dimethylaminomethyl)imidazol-1-yl] phenyl]-1H-pyrazole-5-carboxyamide hydrochloride (razaxaban), a highly potent, selective, and orally bioavailable factor Xa inhibitor
5. Wong PC, Crain EJ, Knabb RM et al (2000) Nonpeptide factor Xa inhibitors: II. antithrombotic evaluation in a rabbit model of electrically induced carotid artery thrombosis. J Pharmacol Exp Ther 295:212-218
6. Gawaz M, Müller I, Besta F (2003) Combined antithrombotic therapy for acute coronary syndrome. Semin Vasc Med 3:163-175
7. Wallentin L (2005) Prevention of cardiovascular events after acute coronary syndrome. Sem Vasc Med 5:293-300
8. Andreotti F, Testa L, Biondi-Zoccai GG, Crea F (2006) Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: An updated and comprehensive meta-analysis of 25,307 patients. Eur Heart J 27:519-526
9. 12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis. Semin Thromb Hemost 31:195-204
10. Himber J, Kirchhofer D, Riederer M, Tschopp TB, Steiner B, Roux SP (1997) Dissociation of antithrombotic effect and bleeding time prolongation in rabbits by inhibiting tissue factor function. Thromb Hemost 78:1142-1149
11. Hollenbach S, Sinha U, Lin P-H et al (1994) A comparative study of prothrombinase and thrombin inhibitors in a novel rabbit model of non-occlusive deep vein thrombosis. Thromb Hemost 71:357-362
12. Refino CJ, Jeet S, DeGuzman L, Bunting S, Kirchhofer D (2002) A human antibody that inhibits factor IX/IXa function potently inhibits arterial thrombosis without increasing bleeding. Arterioscler Thromb Vasc Biol 22:517-522
13. Wong PC, Crain EJ, Watson CA et al (2002) Nonpeptide factor Xa inhibitors III: Effects of DPC423, an orally-active pyrazole antithrombotic agent, on arterial thrombosis in rabbits. J Pharmacol Exp Ther 303:993-1000
14. Mousa SA, Olson RE, Bozarth JM et al (1998) Oral antiplatelet efficacy and specificity of a novel nonpeptide platelet GPIIb/IIIa receptor antagonist, DMP 802. J Cardiovasc Pharmacol 32:169-176
15. Lassen MR, Davidson BL, Gallus A, Pineo G, Ansell J, Deitchman D (2003) A phase II randomized, double-blind, five-arm, parallel-group, dose-response study of a new oral directly-acting factor Xa inhibitor, razaxaban, for the prevention of deep vein thrombosis in knee replacement surgery - on behalf of the razaxaban investigators. Blood 102:111 (Abs 41)
16. Agnelli G, Haas SK, Krueger KA, Bedding AW, Brandt JT (2005) A Phase II study of the safety and efficacy of a novel oral fXa inhibitor (LY517717) for the prevention of venous thromboembolism following TKR or THR. Blood 106:185 (Abs 278)
17. Turpie AG, Fisher WD, Bauer KA et al (2005) BAY 59-7939: An oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study. J Thromb Hemost 3:2479-2486
18. Zafar MU, Gaztanaga J, Velez M et al (2004) A phase-I study to assess the antithrombotic properties of DU-176b: An orally active direct factor-Xa inhibitor. J Am Coll Cardio 47(4, Suppl A):A288 (Abs 908-161)
19. Zafar MU, Viles-Gonzalez J, Valdiviezo C et al (2004) Tissue factor pathway inhibition, a new antithrombotic strategy: Phase-II study of a novel, oral factor Xa inhibitor. J Am Coll Cardio 43(5, Suppl 2):A443 (Abs 1007-173)
20. Leadley RJ Jr (2001) Coagulation factor Xa inhibition: Biological background and rationale. Curr Topics Med Chem 1:151-159
21. Daykin HJ, Sturgeon SA, Jones C, Wright CE (2006) Arterial antithrombotic effects of aspirin, heparin, enoxaparin and clopidogrel alone, or in combination, in the rat. Thromb Res 118:755-762
22. Feuerstein GZ, Patel A, Toomey JR et al (1999) Antithrombotic efficacy of a novel murine antihuman factor IX antibody in rats. Arterioscler Thromb Vasc Biol 19:2554-2562
23. Hong TT, Huang J, Driscoll E, Lucchesi BR (2005) The antithrombotic effect of melagatran in combination with clopidogrel and/or aspirin (carotid artery primary thrombosis study). J Cardiovasc Pharmacol 46:526-533
24. Lorrain J, Lechaire I, Gauffeny C et al (2004) Effects of SanOrg123781A, a synthetic hexadecasaccharide, in a mouse model of electrically induced carotid artery injury: Synergism with the antiplatelet agent clopidogrel. J Pharmacol Exp Ther 309:235-240
25. Eikelboom JW, Weitz JI, Budaj A et al (2002) Clopidogrel does not suppress blood markers of coagulation activation in aspirin-treated patients with non-ST-elevation acute coronary syndromes. Eur Heart J 23:1771-1779
26. Szczeklik A, Krzanowski M, Gora P, Radwan J (1992) Antiplatelet drugs and generation of thrombin in clotting blood. Blood 80:2006-2011